鞘氨醇-1-磷酸受体调节剂使携带NRAS突变的FLT3-ITD急性髓系白血病细胞对FLT3抑制剂重新敏感
本研究探讨S1P与FLT3联合靶向能否克服NRAS突变所致FLT3抑制剂耐药。在NRAS突变的FLT3-ITD AML细胞系及患者原始细胞中,S1PR调节剂芬戈莫德和莫克拉莫德可重新致敏FLT3抑制剂,并在一小鼠模型中验证。
要点
- 芬戈莫德和莫克拉莫德可重新致敏多种NRAS突变型FLT3-ITD AML细胞对FLT3抑制剂敏感。
- 该作用与NRAS突变亚型相关,G12C突变未见重新致敏。
- 联合治疗可灭活ERK、下调SPHK1并灭活AKT、p70 S6K和BAD。
核心结论
- S1PR调节剂芬戈莫德和莫克拉莫德能使NRAS突变的FLT3-ITD AML细胞对FLT3抑制剂重新敏感,支持其潜在临床疗效。
研究设计与样本
- 研究使用NRAS突变的FLT3-ITD AML细胞系和患者原始细胞,以FLT3抑制剂和/或S1PR调节剂处理。
- 通过免疫印迹、细胞毒性、凋亡和集落形成实验评估FLT3抑制剂敏感性。
- 在原位小鼠模型中评估联合治疗在体内的效果。
主要发现
- 芬戈莫德和莫克拉莫德使携带G12D、G12S、Q61K或Q61H但非G12C NRAS突变的MOLM-14和MV4-11细胞对FLT3抑制剂重新敏感。
- 芬戈莫德和莫克拉莫德使携带G13D、G13V或G12D NRAS突变的患者原始细胞对FLT3抑制剂重新敏感。
- 芬戈莫德联合治疗使携带G12D NRAS突变的M14(R)701细胞在体内对吉瑞替尼重新敏感。
- 联合治疗灭活ERK、转录下调SPHK1并灭活下游AKT、p70 S6K和BAD,而组成性SPHK1表达可消除这种灭活作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
FLT3 inhibitor efficacy in AML with FLT3-ITD is short-lived, frequently due to new mutations, most commonly in NRAS. Sphingosine kinase 1 (SPHK1), which phosphorylates sphingosine to generate sphingosine-1-phosphate (S1P), is upregulated and localized to the plasma membrane in RAS-mutated cells. We studied S1P and FLT3 co-targeting to overcome FLT3 inhibitor resistance in NRAS-mutated FLT3-ITD AML cells. NRAS-mutated FLT3-ITD AML cell lines and patient blasts were treated with FLT3 inhibitors and/or S1P receptor (S1PR) modulators. FLT3 inhibitor sensitivity was assessed by immunoblotting, cytotoxicity, apoptosis and colony formation. Co-treatment was also assessed in vivo in an orthotopic mouse model. Downstream RAS and SPHK1 effectors were measured by immunoblotting and qRT-PCR. The S1PR modulators fingolimod (FTY720) and mocravimod (KRP-203) resensitized FLT3-ITD-expressing MOLM-14 and MV4-11 human AML cells with G12D, G12S, Q61K or Q61H, but not G12C, and patient blasts with G13D, G13V or G12D NRAS mutations to FLT3 inhibitors. Moreover, FTY720 co-treatment resensitized G12D NRAS-mutated M14(R)701 cells to gilteritinib in vivo. Co-treatment inactivated ERK, transcriptionally downregulated SPHK1, and inactivated downstream AKT, p70 S6K and BAD, with inactivation abrogated by constitutive SPHK1 expression. The clinically applicable S1PR modulators fingolimod and mocravimod resensitize NRAS-mutated FLT3-ITD AML cells to FLT3 inhibitors, supporting potential clinical efficacy.
引用
- Chatterjee A, Mustafa Ali MK, Bailey CM, et al. Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors. Leukemia. 2026. PMID: 42230959. doi:10.1038/s41375-026-02982-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。